Literature DB >> 11525564

Gene therapy for lysosomal storage disorders.

N S Yew1, S H Cheng.   

Abstract

Deficiencies in one or several of the numerous degradative enzymes that reside in the lysosome often result in one of many clinically severe diseases, almost all of which have no currently available therapy. Although bone marrow transplantation, enzyme replacement and substrate inhibition therapies are being considered, gene therapy represents an increasingly attractive approach, particularly for those lysosomal storage diseases with neurological manifestations. This review summarizes the most recent advances in developing gene therapies for this large and heterogeneous group of disorders.

Entities:  

Mesh:

Year:  2001        PMID: 11525564

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  2 in total

Review 1.  Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

Authors:  Mark Haskins
Journal:  ILAR J       Date:  2009

2.  Possible role of autoantibodies in the pathophysiology of GM2 gangliosidoses.

Authors:  Akira Yamaguchi; Kayoko Katsuyama; Kiyotaka Nagahama; Toshiyuki Takai; Ichiro Aoki; Shoji Yamanaka
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.